SCLX

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

Scilex to list Dream Bowl Tokens on Biconomy, unlock token liquidity

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Scilex announced Dream Bowl Tokens will trade on Biconomy starting July 6, 2026. The company holds about 180 million tokens from distributions; Biconomy reports roughly $2B in daily volume and 10 million users. The move could provide liquidity to participating holders and broaden token distribution, though direct impact on SCLX remains uncertain.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Dream Bowl Tokens begin trading on Biconomy on July 6, 2026.</li><li>Scilex holds about 180 million Dream Bowl Tokens post-distribution.</li><li>Biconomy exchanges 10M+ users and around $2B daily volume.</li><li>Trading may deliver liquidity to Participating Holders and broaden distribution.</li><li>Forward-looking statements warn outcomes may differ.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Scilex Holding Company (SCLX)</strong>: Announced Dream Bowl Token trading; token liquidity may affect shareholder value through crypto exposure.</li><li><strong>Datavault AI Inc. (DVLT)</strong>: Participating holders include DVLT; potential indirect impact if token distributions influence allocations.</li><li><strong>Semnur Pharmaceuticals, Inc.</strong>: Majority-owned subsidiary; SP-102 launcher logic mentioned but not a direct stock driver.</li><li><strong>ZTlido</strong>: Scilex product; part of portfolio context but not a direct equity catalyst from token listing.</li><li><strong>ELYXYB</strong>: Scilex product; separate from token liquidity event but relevant to overall portfolio.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The release centers on a crypto-token liquidity event connected to Scilex’s equity holders, representing a non-core but potentially influential corporate action affecting investor perception of liquidity and crypto exposure.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Biconomy&#039;s liquidity metrics imply meaningful token trading activity for Dream Bowl Tokens.</li><li>180 million tokens create potential liquidity exposure for Scilex holders.</li><li>No direct link to SCLX earnings; valuation impact uncertain.</li><li>Crypto market and regulatory risk could drive token price volatility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Dream Bowl Tokens begin trading on Biconomy on July 6, 2026.</li><li>Scilex holds ~180 million Dream Bowl Tokens after record date April 30, 2026.</li><li>Biconomy: 10M users, 180+ countries, ~$2B daily volume.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Limited near-term impact on SCLX; monitor token liquidity developments over the next 1–3 quarters.</p>
  </section>
</section>


<article>
  <header>
    <h2>Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 06, 2026</h2>
  </header>

  <p>Scilex Holding Company (NASDAQ: <strong>SCLX</strong>), a Palo Alto, California-based innovator focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain as well as neurodegenerative and cardiometabolic diseases, today announced that the Dream Bowl I Meme Coin tokens (<em>Dream Bowl Tokens</em>) commence trading on the Biconomy Exchange on <strong>July 06, 2026</strong>.</p>

  <p>To view the Dream Bowl Tokens now trading on the Biconomy Exchange, please click
  <a href="https://www.biconomy.com/exchange/DREAM1_USDT" rel="nofollow" target="_blank">https://www.biconomy.com/exchange/DREAM1_USDT</a>.</p>

  <section>
    <h3>Trading details and liquidity implications</h3>
    <ul>
      <li><strong>Trading begins</strong> on the Biconomy Exchange on <strong>July 06, 2026</strong> for the <em>Dream Bowl Tokens</em>.</li>
      <li>Trading on the Biconomy Exchange may deliver liquidity and allow broad distribution of such tokens for the stockholders and certain other eligible equityholders of Scilex (collectively, the <em>Participating Holders</em>) that received such tokens in prior distributions by the Company and by Datavault AI Inc (NASDAQ: <strong>DVLT</strong>).</li>
      <li>The Biconomy Exchange serves more than <strong>10 million</strong> users and institutions across <strong>180+</strong> countries and consistently ranks among the top 40 global exchanges by trading volume, with average daily volume of approximately <strong>$2.0 billion</strong>.</li>
      <li>The platform offers hundreds of trading pairs and maintains industry-leading security, with <strong>98%</strong> of assets held in cold storage.</li>
      <li>Scilex currently holds approximately <strong>180 million</strong> Dream Bowl Tokens after the distribution to Participating Holders as of the record date of <strong>April 30, 2026</strong>.</li>
    </ul>
  </section>

  <section>
    <h3>About Scilex Holding Company</h3>
    <p>Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include:
      (i) ZTlido<sup>&#xAE;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the "FDA") for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; 
      (ii) ELYXYB<sup>&#xAE;</sup>, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and 
      (iii) Gloperba<sup>&#xAE;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>

    <p>In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (<em>"SEMDEXA"</em> or <em>"SP-102"</em>), which is owned by Semnur Pharmaceuticals, Inc. (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (<em>"SP-103"</em>), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (<em>"SP-104"</em>), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.</p>

    <p>Scilex is headquartered in Palo Alto, California.</p>
  </section>

  <section>
    <h3>About Semnur Pharmaceuticals, Inc.</h3>
    <p>Semnur Pharmaceuticals, Inc. (<em>"Semnur"</em>) is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA<sup>&#x2122;</sup>), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.</p>

    <p>Semnur is headquartered in Palo Alto, California.</p>
  </section>

  <section>
    <h3>Forward-Looking Statements</h3>
    <p align="justify">This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as <em>"believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook"</em> or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex’s belief that the ability to trade the Dream Bowl Tokens on the Biconomy Exchange may deliver liquidity to the holders thereof and allow broad distribution of such tokens. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risk...</p>
  </section>
</article>

Scilex announced Dream Bowl Tokens will trade on Biconomy starting July 6, 2026. The company holds about 180 million tokens from distributions; Biconomy reports roughly $2B in daily volume and 10 million users. The move could provide liquidity to participating holders and broaden token distribution, though direct impact on SCLX remains uncertain.

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News